|1.||Takahashi, Toshiaki: 5 articles (04/2013 - 09/2006)|
|2.||Aoki, Masashi: 5 articles (04/2013 - 09/2006)|
|3.||Gallardo, Eduard: 4 articles (11/2015 - 06/2006)|
|4.||Angelini, Corrado: 4 articles (12/2014 - 11/2005)|
|5.||Gayathri, N: 4 articles (06/2012 - 07/2008)|
|6.||Nalini, A: 4 articles (06/2012 - 07/2008)|
|7.||Barresi, Rita: 4 articles (05/2011 - 10/2006)|
|8.||Angelini, C: 4 articles (06/2010 - 01/2000)|
|9.||Choi, Young-Chul: 3 articles (06/2015 - 04/2012)|
|10.||Kim, Dae-Seong: 3 articles (06/2015 - 12/2009)|
|1.||Myositis (Idiopathic Inflammatory Myopathies)
12/01/2009 - "The analysis of inflammatory cells, MHC class I expressions and MAC deposits may help to differentiate dysferlinopathy from idiopathic inflammatory myopathy."
12/01/2009 - "Differential immunohistological features of inflammatory myopathies and dysferlinopathy."
06/05/2007 - "Identification of dysferlin expression by IHC and Western blotting are essential for the diagnosis of dysferlinopathy and differential diagnosis of inflammatory myopathy."
06/05/2007 - "Inflammatory cellular infiltrations are relatively common in biopsied muscles of dysferlinopathy patients, which may cause misdiagnosis of inflammatory myopathy. "
01/01/2015 - "Patients with dysferlinopathy also show muscle inflammation, which often leads to a misdiagnosis as inflammatory myopathy. "
|2.||Muscular Dystrophies (Muscular Dystrophy)
06/01/2015 - "Dysferlinopathy comprises a group of autosomal recessive muscular dystrophies caused by mutations in the DYSF gene. "
06/01/2013 - "Dysferlinopathy refers to a group of autosomal recessive muscular dystrophies due to mutations in the dysferlin gene causing deficiency of a membrane-bound protein crucially involved in plasma membrane repair. "
06/01/2012 - "Dysferlinopathy refers to autosomal recessive muscular dystrophies caused by mutations in dysferlin gene (DYSF). "
09/01/2010 - "Fifty-three per cent of the patients were very active and sporty before the onset of symptoms which makes the clinical course of dysferlinopathy unusual within the different forms of muscular dystrophy and provides a challenge to understanding the underlying pathomechanisms in this disease."
08/01/2010 - "Recently, it was reported that a mutation in the dysferlin gene and/or dysferlin deficiency causes proximal and distal forms of muscular dystrophy, which are known by the term dysferlinopathy. "
06/01/2012 - "While the study revealed a consistent pattern of calpain-3 in DMD, one sarcoglycanopathy and three dysferlinopathy samples exhibited secondary reduction in calpain-3. "
04/01/2011 - "Dysferlinopathy was the second most common identifiable cause (21%) of LGMD next to sarcoglycanopathies (27%)."
01/01/2000 - "Dysferlinopathy and sarcoglycanopathy have different and selective muscle involvement. "
01/01/2000 - "In dysferlinopathy, distal lower-limb muscles are involved, while in sarcoglycanopathy proximal muscles are more affected. "
01/01/2000 - "Patients with a definite diagnosis of dysferlinopathy and sarcoglycanopathy were tested for their clinical functions and muscle strength and assigned a functional grade. "
|4.||Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)
01/01/2016 - "We hypothesized that in addition to these actions, halofuginone directly promotes the cell-cycle events of satellite cells in the mdx and dysf(-/-) mouse models of early-onset Duchenne muscular dystrophy and late-onset dysferlinopathy, respectively. "
05/01/2013 - "However in muscular dystrophies, such as Duchenne Muscular Dystrophy and dysferlinopathy, X-ROS signaling operates at a high level and contributes to myopathy. "
01/01/2015 - "Comparative immunohistochemical analysis of inflammatory cell infiltration, and muscle expression of MHC-I and C5b-9 was performed using muscle biopsy samples from 14 patients with dysferlinopathy, 7 patients with polymyositis, and 8 patients with either Duchenne muscular dystrophy or Becker muscular dystrophy (DMD/BMD). "
06/01/2012 - "Calpain-3 Western blot analysis in muscle biopsies of immunohistochemically confirmed cases of Duchenne muscular dystrophy (DMD) (n=10), dysferlinopathy (n=30) and sarcoglycanopathy (n=8) was carried out. "
05/01/2006 - "Thirty-eight had LGMD2I (27 homozygous, 11 compound heterozygous for 826C>A), 23 had sarcoglycanopathy, 2 dysferlinopathy, 12 calpainopathy, and 4 Becker muscular dystrophy. "
|5.||Myotonic Dystrophy (Dystrophia Myotonica)
06/01/2010 - "A systematic clinical evaluation based on the Medical Research Council scale and MRI was completed in ten patients with calpainopathy [limb-girdle muscular dystrophy (LGMD)-2A], 16 with dysferlinopathy (LGMD-2B), ten with hyaline body myopathy (HBM), six with myotonic dystrophy (MD) types 1 and 5 with MD type 2. Severity of fibroadipose degeneration was specifically staged using T1-weighted sequences. "
01/01/2013 - "Spinal muscular atrophy (SMA), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy (DMD), Fukuyama congenital muscular dystrophy (FCMD), dysferlinopathy (including limb-girdle muscular dystrophy 2B; LGMD2B, Miyoshi myopathy; MM, and distal myopathy with anterior tibial onset; DMAT), and myotonic dystrophy (DM) are all reported to be promising targets for antisense therapy. "
06/01/2006 - "Summary of Neuromuscular Presentations at the 57 Annual AAN 2005 meeting in Miami Florida on topics of Facioscapulohumeral muscular dystrophy (FSHD), Duchenne muscular dystrophy (DMD), Diabetic Neuropathy, Charco Marie Tooth disease (CMT), Comparison of injected steroids versus Surgery for carpal tunnel syndrome, Rituximab in Anti-MAG associated polyneuropathy, Cannabis based medicine (CBM) in the treatment of neuropathic pain, utility of skin biopsy with intraepidermal nerve fiber density (IENFD) in sensory complaints, comparing sympathetic skin responses (SSRs) and skin biopsy in diagnosing small fiber sensory neuropathy, Chronic inflammatory demyelinating polyneuropathy (CIDP) clinical and electrophysiologic predictors, affect of limb warming in mild ulnar nerve conduction study (NCS) abnormalities, Tamoxifen affect in ALS, open label study of 3,4 DAP, Pyridostigmine and Ephedrine in fast channel syndrome, Mexilitine as an antimyotonia treatment in myotonic dystrophy (DM1), frontal lobe impairment evaluation in DM1 and DM2 patients and phenotype-genotype correlation in patients with dysferlinopathy."
|2.||Complement Membrane Attack Complex (Membrane Attack Complex)
|5.||Pyridostigmine Bromide (Pyridostigmine)
|8.||Limb-girdle muscular dystrophy type 2A
|10.||Creatine Kinase (Creatine Phosphokinase)